NHS7108 is an orally administered lipase, or fat-digesting enzyme.

It was engineered to be highly stable in the acidic conditions in the stomach, so it can reach the small intestine where digestion mostly takes place. It is also designed to be resistant to protein-degrading enzymes in the upper intestine. NHS7108 could eventually provide an alternative to existing pancreatic enzyme products.

Status

A Phase 2 study to test the safety and effectiveness of different doses of NHS7108 is planned. The study is for people with CF who are currently taking pancreatic enzymes.

Sponsor

This program is sponsored by Nestlé Health Science. It is being conducted within the Therapeutics Development Network.